MR comparative study of combined hepatocellular-cholangiocarcinoma in normal, fibrotic, and cirrhotic livers.

Abdom Radiol (NY)

Department of Radiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China.

Published: November 2016

Purpose: To compare MR imaging features of combined hepatocellular-cholangiocarcinoma (cHCC-CC) in normal, fibrotic, and cirrhotic livers.

Methods: A total of 64 patients with 67 pathologically proven cHCC-CCs were retrospectively analyzed. Patients were classified into three groups according to the patients' liver condition: patients with normal liver (F0, group 1), fibrosis without cirrhosis (F1-3, group 2), and cirrhosis (F4, group 3). The morphological and MR signal features on T1- and T2-weighted, dynamic contrast-enhanced, diffusion-weighted imaging, as well as the accompanying imaging findings, were evaluated and compared.

Results: There were 12, 19, and 33 patients in groups 1, 2, and 3, respectively. Tumors in the fibrotic and cirrhotic livers were smaller than those in the normal liver, and tumors with cirrhosis had the smallest size (P = 0.0326). No statistical difference was found when comparing the signal intensity on T2-weighted imaging (P = 0.496), but iso- or hypointense lesions were only found in the fibrosis (n = 2) or cirrhosis group (n = 2). Enhancement pattern was different between groups, the washout pattern was more often seen in the cirrhosis group (P = 0.049), and the accompanying mosaic architecture was also more commonly seen in the cirrhosis group (P = 0.048). The ADC values of the lesions were not different among the three groups (P = 0.899).

Conclusion: MRI may provide valuable information for the diagnosis and differential diagnosis of cHCC-CC in normal, fibrotic, and cirrhotic livers. The nodule size, enhancement pattern, and the presence of mosaic architecture in cHCC-CC differ between different degrees of background liver disease.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-016-0811-yDOI Listing

Publication Analysis

Top Keywords

fibrotic cirrhotic
16
cirrhosis group
16
normal fibrotic
12
cirrhotic livers
12
combined hepatocellular-cholangiocarcinoma
8
chcc-cc normal
8
three groups
8
normal liver
8
enhancement pattern
8
mosaic architecture
8

Similar Publications

Article Synopsis
  • A method was developed to model liver cirrhosis in male Wistar rats by performing a significant liver resection (about 70% volume).
  • After surgery, one group received ademetionine while the control group got saline; both had various tests conducted on them over a 14-day period.
  • Results indicated that the ademetionine group experienced notable liver dysfunction, with laboratory tests showing significant abnormalities, along with observable fibrotic, cirrhotic, and inflammatory liver changes that persisted beyond the testing period.
View Article and Find Full Text PDF
Article Synopsis
  • Cirrhotic cardiomyopathy is characterized by both systolic and diastolic dysfunction in patients with cirrhosis, resulting from abnormalities in heart muscle cells (cardiomyocytes) without any underlying heart disease.
  • Changes at the cellular level include altered membrane fluidity and dysfunctional receptors (like beta-adrenergic), as well as issues with calcium and ion transport processes, impacting overall heart function.
  • The heart in cirrhotic patients also undergoes fibrotic changes similar to those in the liver, leading to stiffness and further dysfunction, compounded by excessive cell death of cardiomyocytes.
View Article and Find Full Text PDF

To investigate the effect of laparoscopic splenectomy and azygoportal disconnection (LSD) on liver synthesis and development of liver cirrhosis. This is a prospective case series study.The clinical data of liver cirrhotic patients with portal hypertension who received LSD at the Department of Hepatobiliary Surgery of Northern Jiangsu People's Hospital Affiliated to Yangzhou University from September 2014 to January 2016 were included.

View Article and Find Full Text PDF

Background: The therapeutic effect of mesenchymal stem cells (MSCs) in liver cirrhosis is limited by their entrapment in the pulmonary vessels. Thus, the use of MSC-derived exosomes has become a promising strategy. The current work aimed to compare the role of human umbilical cord blood-MSCs (hUCB-MSCs) and their derived exosomes in the alleviation of liver cirrhosis focusing on the role of miR-23b and miR-221 and their direct effectors in inflammatory and autophagic pathways.

View Article and Find Full Text PDF

Artesunate: A potential drug for the prevention and treatment from hepatitis to hepatocellular carcinoma.

Pharmacol Res

December 2024

TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China; Department of Gastroenterology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. Electronic address:

Liver cancer represents a multifactorial, multistage, and intricately progressive malignancy. Over the past decade, artesunate (ART), initially renowned for its anti-malarial efficacy, has been the focus of over 3000 studies uncovering its diverse pharmacological actions, including anti-inflammatory, immunoregulatory, metabolic regulatory, anti-fibrotic, and anti-cancer properties. This review highlights ART's role in the multistep progression from hepatitis to cancer and its underlying regulatory mechanisms, revealing signal transducer and activator of transcription 3 (STAT3) and ferroptosis (a novel form of programmed cell death) as promising therapeutic targets.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!